BioInformant

Your Global Leader in Stem Cell Market Research

Home » CAR-T » Page 2

Types of CAR-T Cells: Improvements in CAR Design and Construction

By

What are the types of CAR-T cells and how have they changed in recent years? CAR-T cells are immune cells that are artificially engineered to express a particular chimeric antigen receptor (CAR), which have shown great potential in killing cancer cells. Chimeric antigen receptors (CARs) are artificially produced recombinant receptors having both antigen-binding and T-cell activating potentials.

CARs are composed of an extracellular recognition domain sourced from monoclonal antibodies (mAbs) and an intracellular signaling domain including CD3- and costimulatory domains for triggering endogenous signaling pathways of T-cells. [Read more…]

Genetic Modification of CAR-T Cells

By

Chimeric antigen receptor-modified T (CAR-T) cells are living therapies that are genetically engineered to express CAR molecules targeting antigens found on tumor cells or target cells of interest. Unfortunately, an obstacle for the field of CAR-T cell therapy is limited CAR T cell persistence after infusion into cancer patients. Thus, genetic engineering strategies to improve CAR T cell persistence will be central to the success of these gene-modified cellular therapies. [Read more…]

INTELLiSTEM Announces the Launch of a New Antigen Identification Platform for the Development of Novel CAR T Cells

By

TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy,  announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]

CAR-T Cell Therapy Attracts Vast Sums of Money

By

What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.

Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]

Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility

By

CellectisCellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.

Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.

Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]

BioInformant's World-Class Clients